This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ventas Secures Agreements With Kindred & ScionHealth for 23 LTACs
by Zacks Equity Research
To improve patient care facilities, VTR announces reaching an agreement with Kindred and ScionHealth regarding 23 long-term acute care hospitals.
Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYD
Here's Why You Should Retain Ventas Stock in Your Portfolio Now
by Zacks Equity Research
Rising healthcare spending and aging population aid Ventas' senior housing operating portfolio. However, tenant concentration and high interest rates are risks.
Ventas (VTR) Stock Rises 34.1% in Six Months: Here's How
by Zacks Equity Research
Ventas (VTR) is poised to gain from a favorable demand in senior housing, backed by an expected rise in senior citizens' population despite the high interest rates environment.
What's in the Cards for Medical Properties (MPW) in Q2 Earnings?
by Zacks Equity Research
While Medical Properties' (MPW) Q2 earnings are likely to have benefited from the favorable healthcare industry trends, high interest rates and exposure to certain troubled operators may have hurt it.
OUTFRONT Media (OUT) Q2 AFFO Beats Estimates, Revenues Miss
by Zacks Equity Research
OUTFRONT Media's (OUT) Q2 AFFO results reflect lower operating expenses driven by lower property lease costs.
Ventas (VTR) Q2 FFO Beats Estimates on Higher Same-Store NOI
by Zacks Equity Research
Ventas' (VTR) Q2 results reflect occupancy and revenue growth in its same-store senior housing operating portfolio.
Compared to Estimates, Ventas (VTR) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Ventas (VTR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ventas (VTR) Q2 FFO and Revenues Top Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 1.27% and 0.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Extra Space Storage (EXR) Q2 FFO Tops Estimates, Occupancy Rises
by Zacks Equity Research
Extra Space Storage's (EXR) Q2 results reflect higher occupancy. However, higher same-store operating expenses and increased interest expenses act as a spoilsport.
Public Storage (PSA) Beats Q2 FFO Estimates, Trims Guidance
by Zacks Equity Research
Public Storage's (PSA) Q2 results reflect lower realized annual rent per occupied square foot and a decline in occupancy.
What to Expect From VICI Properties (VICI) in Q2 Earnings?
by Zacks Equity Research
VICI Properties' (VICI) Q2 earnings are likely to reflect the company's accretive expansion moves and the benefits of owning a high-quality portfolio with a diverse revenue base.
Ventas (VTR) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Ventas (VTR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
What to Expect From American Tower (AMT) in Q2 Earnings?
by Zacks Equity Research
American Tower's (AMT) Q2 earnings are likely to have benefited from the solid demand for its communication real estate portfolio, though high interest expenses and elevated churn remain concerns.
What's in the Offing for Ventas (VTR) This Earnings Season?
by Zacks Equity Research
Ventas' (VTR) Q2 earnings are likely to have benefitted from favorable SHOP operating trends, healthy demand for life-science real estate assets and accretive investments.
Welltower (WELL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Welltower's (WELL) Q2 earnings are expected to have benefited from the rise in the senior citizen population and this age cohort's high healthcare expenditure. However, high interest expenses remain a concern.
Digital Realty (DLR) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Digital Realty's (DLR) Q2 earnings are likely to have been aided by solid data center demand and acceleration in digital transformation strategies. However, high interest expenses may have been a concern.
Alexandria (ARE) Q2 AFFO Beats Estimates, Revenues Miss
by Zacks Equity Research
Alexandria's (ARE) Q2 AFFO outshines estimates. Results reflect decent leasing activity and higher rental rates.
What's in the Cards for Healthpeak (DOC) This Earnings Season?
by Zacks Equity Research
While Healthpeak's (DOC) Q2 earnings are likely to have benefited from the healthy demand for lab real estate assets, high interest expenses raise concern.
Here's Why You Should Retain Ventas (VTR) in Your Portfolio
by Zacks Equity Research
Ventas (VTR) is poised to benefit by leveraging the rise in the aging population, growing outpatient visit trends and a healthy balance sheet. However, higher competition and interest rates are headwinds.
Ventas (VTR) Hits 52-Week High: Will the Stock Trend Higher?
by Zacks Equity Research
Ventas (VTR) is expected to continue to benefiting from a favorable senior housing operating portfolio and outpatient visit trends.
Ventas (VTR) Stock Rises 11.4% in Three Months: Here's How
by Zacks Equity Research
Ventas (VTR) is poised to gain from a favorable demand in senior housing, backed by an expected rise in senior citizens' population despite the high interest rates environment.
Ventas (VTR) Up 6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ventas (VTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ventas (VTR) Sees Occupancy Growth in 2024 on Strong Demand
by Zacks Equity Research
Ventas' (VTR) properties continue to expect occupancy growth in 2024, backed by strong demand.
What's in the Cards for Medical Properties (MPW) in Q1 Earnings?
by Zacks Equity Research
While Medical Properties' (MPW) Q1 earnings are likely to have benefited from the favorable healthcare industry trends, the high interest rate environment may have hurt it.